Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Hua MedicineHUMDF 44 Debt-to-Equity is 0.30 as of Dec. 2025, which is 88% above its 10-year median of 0.16. GuruFocus rates HUMDF with a GF Score™ of 44/100 and a GF Value™ of $1.18 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 815 Drug Manufacturers companies, Hua Medicine ranks worse than 52.27% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Hua Medicine's Debt-to-Equity or its related term are showing as below:
HUMDF'
s Debt-to-Equity Range Over the Past 10 Years
Min: -2.22 Med: 0.16 Max: 1.66
Current: 0.3
During the past 10 years, the highest Debt-to-Equity Ratio of Hua Medicine was 1.66. The lowest was -2.22. And the median was 0.16.
HUMDF's Debt-to-Equity is ranked worse than 52.27% of 815
companies
in the Drug Manufacturers industry
Industry Median: 0.28
vs HUMDF: 0.30
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Hua Medicine Debt-to-Equity Related Terms
Hua Medicine Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Hua Medicine's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Hua Medicine's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hua Medicine Debt-to-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Hua Medicine's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Hua Medicine's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hua Medicine (HUMDF) has a Debt-to-Equity of 0.30 as of Dec. 2025. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Hua Medicine and its competitors. This is 88% above median its historical median of 0.16. According to the industry distribution chart, Hua Medicine ranks #426 out of 815 companies in the Drug Manufacturers industry, placing it in the top 52.3%.
Is Hua Medicine's Debt-to-Equity too high?
Hua Medicine's current Debt-to-Equity of 0.30 is 88% above median its 10-year median of 0.16. The Drug Manufacturers industry median Debt-to-Equity is 0.28. Hua Medicine's value of 0.30 is 7.1% above this industry median. Based on the distribution chart, Hua Medicine ranks #426 out of 815 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Hua Medicine has a GF Score™ of 44/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Hua Medicine's Debt-to-Equity compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Hua Medicine ranks #426 out of 815 companies for Debt-to-Equity. This places Hua Medicine in the lower half of its industry. The industry median Debt-to-Equity is 0.28. Hua Medicine's value of 0.30 is 7.1% above this benchmark. While the company's 10-year median is 0.16 vs. the industry median of 0.28, Hua Medicine has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Drug Manufacturers company?
The median Debt-to-Equity among Drug Manufacturers companies is 0.28, based on 815 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Hua Medicine's current Debt-to-Equity of 0.30 is 7.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Hua Medicine and its competitors. For the Drug Manufacturers industry, the median Debt-to-Equity is 0.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hua Medicine's current Debt-to-Equity is 0.30, which is 88% above median its own 10-year median of 0.16. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hua Medicine stock overvalued right now?
Based on GuruFocus' analysis, Hua Medicine (HUMDF) is currently considered Possible Value Trap. The stock's GF Value™ is $1.18, compared to a current price of $0.31 — trading 73.4% below its estimated fair value. The current Debt-to-Equity is 0.30, which is 88% above median its 10-year median of 0.16 and 7.1% above the Drug Manufacturers industry median of 0.28. Hua Medicine's overall GF Score™ is 44/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Hua Medicine (HUMDF), the current Debt-to-Equity is 0.30 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Hua Medicine (HUMDF) Overvalued in 2026?
Based on GuruFocus' analysis, Hua Medicine stock appears to be undervalued.
The current stock price of $0.31 is trading 73.4% below its estimated GF Value™ of $1.18.
GuruFocus considers Hua Medicine to be Possible Value Trap.
Key valuation signals for HUMDF:
Debt-to-Equity: 0.30 (88% above median its 10-year median of 0.16)
GF Value™: $1.18 vs. price of $0.31 (73.4% below fair value)
Industry Position: 7.1% above the Drug Manufacturers median (#426 of 815)
No single metric tells the full story. See the HUMDF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Hua Medicine is an investment holding company. It is engaged in the development and commercialization of a first-in-class oral drug, Dorzagliatin (HMS5552), for the treatment of Type 2 diabetes. Dorzagliatin is a first-in-class glucokinase activator, or GKA, designed to control the progressive degenerative nature of diabetes by restoring glucose homeostasis in Type 2 diabetes. The group majorly operates and generates the majority of its revenue from the PRC.
44GF Score
Get the complete analysis for HUMDF
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HUMDF has been successfully added to your 
